Well-known somatic drivers of glioblastoma (GBM) heterogeneity, including PDGFRA, IDH1, EGFR, and NF1, have altered how we treat patients, diagnose disease, and design clinical trials (1, 2). The gene discussed is PDGFRA; the disease is glioblastoma.